News in brief: Proteomic markers may identify aggresive CLL; Haematologist wins AMA award; Heparin mimetics may be next COVID-19 therapy

Proteomic markers may identify aggressive CLL Proteomic profiles of B cells in the early stage of chronic lymphocytic leukaemia (CLL) can discriminate progressive from stable disease, according to French researchers. A team at the Department of Haematology, University Hospital of Brest, also showed that that RNA splicing dysregulation underlies CLL evolution, which they say opens ...

Already a member?

Login to keep reading.

© 2021 the limbic